Ovarian cancer
Conditions
Interventions
Apatinib combined with oxaliplatin treatment group:Apatinib Tablets orally
Sponsors
Xin qiao Hospital, Chong qing
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged =18 years old; 2. Pathologically diagnosed with platinum-resistant advanced recurrent or metastatic ovarian cancer previously treated with standard cisplatin regimens; 3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 2. 4. Life expectancy of at least 3 months. 5. The main organ function meeting the following: (1) blood routine examination meeting the standards (no blood transfusion and blood components support within 14 days, not using G-CSF and other hematopoietic stimulating factor correction: HB = 90 g/L; ANC = 1.5×10^9/L; PLT = 60×10^9/L; (2) blood biochemical examination meeting the following standards: TBIL <2 times the upper limit of normal (ULN); ALT and AST <5×upper limit of normal(ULN); serum Cr=1.5 times the upper limit of normal (ULN). 6. participants volunteered to participate in this study, signed informed consent, compliance, with follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with uncontrol hypertension in the use of two antihypertensive drugs (systolic blood pressure = 140 mmHg or diastolic blood pressure = 90 mmHg, despite optimal drug therapy); 2. Patients with grade II myocardial ischemia or myocardial infarction, poor control of arrhythmias (including QTc interval male = 450 ms, female =470 ms); 3. Cagulation abnormalities. Patients with bleeding tendency, receiving thrombolytics or anticoagulants; 4. Patients with a history or clear tendency of gastrointestinal bleeding in the period of 6 months can not be allowed to join the study. such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood ++ and above, or suffering from vasculitis; 5. Known hereditary or acquired bleeding and thrombophilia (eg hemophilia, coagulopathy, thrombocytopenia, hypersplenism, etc); 6. Long-term, unhealed wounds or fractures; 7. There are several factors that affect oral medicine,such as unable to swallow, chronic diarrhea; 8. The first 6 months before the group appeared abdominal fistula, gastrointestinal perforation or abdominal abscess; 9. Positive urinary protein(uric albumen check(++),or Twenty-four hours urinary protein content>1.0g); 10. A large number of serous effusion (including pleural effusion, ascites, pericardial effusion); 11. Persons who have history of psychotropic substance abuse who can not be abstinent or who have mental disorders; 12. 4 weeks before enrollment in other anti-cancer drug clinical trials; 13. previous or concurrent with other untreated malignancies except cured basal cell carcinoma of the skin, carcinoma of the cervix in situ, and superficial bladder cancer; 14. Conditions determined by investigators to possibly affect the clinical study or determination of the study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;AE;SAE; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;DCR;ORR;vital signs;Laboratory indicators; | — |
Countries
China
Contacts
Public ContactHao Ping
Xinqiao Hospital, Chongqing
Outcome results
None listed